Terms ending in 2031
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2031, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,426,402 | Novel Benzodiazepine Derivatives In force · High confidence | ImmunoGen Inc. | In force | High confidence | |
| US 8,557,966 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,598,490 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,657,100 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,670,278 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,670,279 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,670,280 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 10,752,683 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 10,202,460 | CD37-Binding Molecules and Immunoconjugates Thereof In force · Medium confidence | Debiopharm International, S.A. | In force | Medium confidence | |
| US 10,301,385 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| 4 more term ends in 2031 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
13 of these are in force and held by ImmunoGen, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.